Please login to the form below

Not currently logged in

Kala Pharma appoints Fovea founder Bernard Gilly to board

He previously formed the company that became Sanofi’s ophthalmology business

Dr Bernard Gilly, founder and CEO of Sanofi-owned Fovea, has joined the board of Kala Pharmaceuticals.

He brings years of experience in eye treatment to Kala, which is developing mucosal penetrating products in a number of ophthalmic diseases.

“Dr Gilly is a seasoned entrepreneur in the biotechnology industry having spent over 20 years building and investing in leading life science companies,” said Dr Guillaume Pfefer, Kala's president and CEO.

“His track record and expertise in the ophthalmology space is an invaluable addition to Kala as we advance our pipeline of transformative ophthalmic products into the clinic.”

Dr Gilly, along with Professor Jose Sahel and Pierre Belichard, set up Fovea in 2005. The company was acquired by Sanofi in 2009, becoming the French pharma firm's ophthalmology division.

Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.

He also served as a co-president and VP of R&D of Sanofi Pasteur and VP of R&D of BioMérieux.

His other entrepreneurial efforts include helping to found several biotech companies, including Domain Therapeutics, WebSurg, Kutexis, GenSight Biologicals, Pixium Vision and Enterome. He currently serves as chair at the latter three companies.

29th November 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge